Billets de Michelle Dawson

Billet publié sur Twitter/X le 05/09/2021 13:12

Retour aux billets Billet précédent Billet suivant
Twitter/X Essai clinique clinicaltrials.gov Extrait cité dans le billet Question posée par Dawson dans le billet Lien intégré au billet Termes sur l’autisme
Ouvrir le billet original

Infos sur le lien intégré au billet

Essai clinique

Johns Hopkins University, Charlotte's Web, Inc (2023). Cannabidiol (CBD) in Adults With ASD. ClinicalTrials.gov. Johns Hopkins University.

Plus d’infos

Liens cités structurés

1 ressource citée

Essai clinique Récupéré Publication clinicaltrials.gov

Johns Hopkins University, Charlotte's Web, Inc (2023). Cannabidiol (CBD) in Adults With ASD. ClinicalTrials.gov. Johns Hopkins University.

Date de publication
20/04/2023
Identifiant
NCT05015439
Auteurs
Johns Hopkins University, Charlotte's Web, Inc
Source
ClinicalTrials.gov
Type de référence
clinical_trial
Éditeur
Johns Hopkins University
Source de métadonnées
clinicaltrials.gov

Résumé

There are no FDA approved treatments for use in adults with autism spectrum disorder (ASD), many of whom have distressing anxiety, mood disturbances, sleep problems, and agitation. Some researchers and individuals with ASD have noted that cannabidiol (CBD) is beneficial for those psychiatric problems. This study is to learn more about the effectiveness and safety of CBD in the treatment of psychiatric problems in adults with ASD. The study will last 14 weeks total, during which six weeks participants will receive a pill containing CBD, two weeks where participants will receive no drug/placebo, and six weeks where participants will receive the placebo, an inactive pill. As part of the study, participants will have regular visits and be asked questions about anxiety, challenging behaviors, daily functioning, cognition, and physical symptoms, on standard assessments.

Ouvrir la source Lien vers la source citée